In this session you will hear from experts in supportive care for patients with acute lymphoblastic leukemia (ALL) with a special focus on asparaginase and high-dose methotrexate.

Learning Objectives
• Consider implications when switching from short-acting to long-acting asparaginase in frontline therapy
• Prevent and manage toxicities of high-dose methotrexate
• Identify, diagnose, and manage infusion reactions to peg-asparaginase

Disclaimer:
SIOP accepts that the content on this page meets the essential criterion of non-promotional intent and that it is of educational and scientific relevance to the SIOP target audience.

Supported by an unrestricted educational grant from Servier and SERB.